Alternatively, the difference in MS risk between these strains could be due to increased susceptibility to HHV-6A infection of KIR2DL2-carrying MS patients or to U24-mediated disruption of MBP-Fyn interactions which stabilise myelin (188, 189), and further research is needed to elucidate the exact mechanisms of HHV-6A in MS. The gene discussed is MBP; the disease is myeloid sarcoma.